Ligand validation:2VCK

BLA: BILIVERDINE IX ALPHA

BLA is a Ligand Of Interest in 2VCK designated by the RCSB

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
2VCK_BLA_C_1234	60%	23%	0.132	0.917	1.47	1.86	8	9	3	0	100%	1
2VCK_BLA_D_1234	59%	29%	0.122	0.905	1.58	1.39	5	8	0	0	100%	1
2VCK_BLA_A_1234	46%	28%	0.146	0.88	1.47	1.58	5	8	2	0	100%	1
2VCK_BLA_B_1234	45%	28%	0.145	0.878	1.6	1.43	5	8	3	0	100%	1
2X9J_BLA_A_1234	84%	28%	0.087	0.948	1.63	1.38	7	6	3	0	100%	1
2X9I_BLA_C_1234	67%	23%	0.134	0.942	1.61	1.73	4	13	6	0	100%	1
2VGR_BLA_C_1234	34%	29%	0.156	0.837	1.65	1.33	6	8	4	0	100%	1
5B4J_BLA_A_301	98%	19%	0.055	0.981	2	1.61	10	5	0	0	100%	1
5VIQ_BLA_A_401	95%	5%	0.067	0.97	2.99	2.59	16	21	1	0	100%	1
3NB8_BLA_A_249	95%	10%	0.068	0.97	2.56	1.99	11	12	0	0	100%	1
7E2S_BLA_A_301	94%	10%	0.063	0.962	2.91	1.56	18	7	0	0	100%	1
5VIK_BLA_A_401	94%	8%	0.068	0.967	2.82	2.1	14	17	3	0	100%	1

RCSB PDB Core Operations are funded by the National Science Foundation (DBI-1832184), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM133198.